Non-Squamous NSCLC

Treatment of EGFR/ALK/ROS1 mutations should take priority over any other mutations e.g. MET. Immunotherapy (alone or in combination with chemotherapy) is not an appropriate first line treatment choice in the presence of these mutations, regardless of PDL1 status. Please refer to the appropriate pathway for preferred treatment choices.

In the presence of concurrent mutations (EGFR/ALK/ROS1) further consideration should be given to wider patient and diagnostic picture. Consider additional support from literature, peers etc.

Throughout the patient pathway, consideration should be given to patient preference, performance status and other relevant patient factors.

Patient eligibility and suitability for available clinical trials should be considered and discussed with individual patients as appropriate.